Yuen, C., Artz, A., Kelly, T., Wu, S., Reder, A., Rezania, K., . . . Bishop, M. (2019). NCMP-08. CLINICAL FEATURES OF CAR T-CELL THERAPY NEUROTOXICITY AS POTENTIAL SURROGATE MARKERS FOR PROGRESSION AND OUTCOME. Neuro Oncol.
Styl cytowania ChicagoYuen, Carlen, et al. "NCMP-08. CLINICAL FEATURES OF CAR T-CELL THERAPY NEUROTOXICITY AS POTENTIAL SURROGATE MARKERS FOR PROGRESSION AND OUTCOME." Neuro Oncol 2019.
Styl cytowania MLAYuen, Carlen, et al. "NCMP-08. CLINICAL FEATURES OF CAR T-CELL THERAPY NEUROTOXICITY AS POTENTIAL SURROGATE MARKERS FOR PROGRESSION AND OUTCOME." Neuro Oncol 2019.
Uwaga: Te cytaty mogą odróżniać się od wytycznej twojego fakultetu..